Full Breakdown
Appointment of Dr. Harvey Risch as Chair of the President's Cancer Panel Raises Concerns
12/17/2025, 10:57:25 AM
Overview of the Appointment
Dr. Harvey Risch, a professor emeritus of epidemiology at Yale University, has been appointed by President Donald Trump as the chair of the President's Cancer Panel, a key oversight body for the National Cancer Program. The announcement was made by the Department of Health and Human Services (HHS) on a Tuesday, following Risch's own declaration of the appointment earlier in the month. Risch's role will involve monitoring the development and execution of cancer-related activities and reporting progress to the President.
Background of Dr. Harvey Risch
Risch is known for his controversial positions on COVID-19 treatments, having been an early advocate for hydroxychloroquine and ivermectin. He has also speculated about a potential link between COVID-19 vaccines and a phenomenon he terms "turbo cancer" in young individuals. His appointment has sparked significant concern among medical professionals regarding the potential influence of his views on the National Cancer Program, which is designed to coordinate critical cancer research and funding.
Concerns from Medical Experts
Experts have expressed alarm over Risch's appointment, fearing that his promotion of unproven treatments and conspiracy theories could undermine serious cancer research efforts. David Gorski, a surgical oncologist, labeled Risch's inclusion on the panel as a "disaster for cancer patients," suggesting that it could lead to the incorporation of pseudoscience into official reports. An anonymous expert echoed these concerns, stating apprehension about the promotion of ivermectin for cancer treatment at a federal level.
Official Statements on the Appointment
The HHS emphasized Risch's extensive background in cancer research, noting his work on various cancer types, including ovarian, pancreatic, and lung cancers. Risch himself expressed gratitude for the opportunity, stating, “We are sitting on the treasure trove of knowledge necessary to demystify the causes of cancer.” He aims to enhance public awareness regarding factors influencing cancer etiology, including dietary and environmental influences.
Support from Government Officials
HHS Secretary Robert F. Kennedy, Jr. praised Risch's expertise, asserting that he would confront the factors driving cancer rates and provide the public with trustworthy science. NIH Director Jay Bhattacharya remarked on the evolving understanding of cancer prevention, indicating that significant developments in the field should be anticipated.
Conflicting Reports & Gaps
While the HHS confirmed Risch's appointment, there was a notable delay of 11 days between Risch's announcement and the official confirmation. Additionally, Risch's name was not initially listed on the Cancer Panel's website, raising questions about the transparency of the appointment process.
Conclusion
Dr. Harvey Risch's appointment as chair of the President's Cancer Panel has ignited a debate over the intersection of public health policy and controversial medical opinions. As he steps into this influential role, the implications of his views on cancer treatment and prevention will be closely monitored by both supporters and critics alike.
